Drug
ME-344
ME-344 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_1
3
75%
Ph early_phase_1
1
25%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (25.0%)
Phase 13 (75.0%)
Trials by Status
completed250%
terminated250%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_1
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
NCT05824559
completedearly_phase_1
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
NCT02806817
terminatedphase_1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
NCT02100007
completedphase_1
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
NCT01544322
Clinical Trials (4)
Showing 4 of 4 trials
NCT05824559Phase 1
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
NCT02806817Early Phase 1
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
NCT02100007Phase 1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
NCT01544322Phase 1
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4